A novel non-invasive biomarker for assessment of small intestinal mucositis in children with cancer undergoing chemotherapy

Date

2006

Authors

Tooley, K.
Saxon, B.
Webster, J.
Zacharakis, B.
McNeil, Y.
Davidson, G.
Butler, R.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Cancer Biology & Therapy, 2006; 5(10):1275-1281

Statement of Responsibility

Tooley, Katie L ; Saxon, Ben R ; Webster, Judy ; Zacharakis, Betty ; McNeil, Yvette ; Davidson, Geoffrey P ; Butler, Ross N

Conference Name

Abstract

Background: Small intestinal mucositis is a common side-effect following high-dose chemotherapy, causing patients to experience pain and abdominal complications often leading to extended stays in hospital. A biomarker to detect these small intestinal changes does not exist in clinical practice. This study aimed to assess the non-invasive 13C-Sucrose breath test (SBT) to detect small intestinal damage associated with mucositis in pediatric cancer patients having chemotherapy. Patients and Methods: Small intestinal function was assessed in 15 pediatric cancer patients and 26 healthy children. Subjects were studied for small intestinal permeability (SIP; lactulose/rhamnose), digestive and absorptive capacity (SBT; sucrose), and oro-cecal transit time (OCTT; lactulose), by ingesting two sugar drinks containing the respective sugars. Combined tests were carried out at baseline, day1, day3-5 and day6-9, and in healthy individuals on two separate occasions. A total of 25 cycles of chemotherapy were assessed. Breath samples for the SBT were collected every 15min for 3 h (expressed as % cumulative dose at 90min (CD)), a 5 h urine collection for SIP and breath hydrogen determined every 30min for 3 h for OCTT. Results: Clinical mucositis occurred in seven of the 25 cycles of chemotherapy (28%). No significant difference was observed for SIP and OCTT. The SBT %CD at 90min was significantly lower in the mucositis group compared to the unaffected group and controls at baseline (p < 0.05). Patients who developed mucositis maintained a significantly lower %CD, for all test points (p < 0.05) compared to the unaffected patients. In patients who developed mucositis the SBT was below the reference range of the controls at all time points. Conclusion: The findings show for the first time that it is possible to non-invasively detect and monitor gut damage associated with chemotherapy-inducedmucositis in pediatric cancer patients.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

License

Grant ID

Call number

Persistent link to this record